The key glycolytic enzyme phosphofructokinase is involved in resistance to antiplasmodial glycosides

Gillian M Fisher
Griffith University

Simon A Cobbold
University of Melbourne

Andrew Jezewski
Washington University School of Medicine in St. Louis

Emma F Carpenter
Wellcome Sanger Institute

Megan Arnold
Griffith University

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Please let us know how this document benefits you.

Recommended Citation
Fisher, Gillian M; Cobbold, Simon A; Jezewski, Andrew; Carpenter, Emma F; Arnold, Megan; Cowell, Annie N; Tjhin, Erick T; Saliba, Kevin J; Skinner-Adams, Tina S; Lee, Marcus C S; Odom John, Audrey; Winzeler, Elizabeth A; McConville, Malcolm J; Poulsen, Sally-Ann; and Andrews, Katherine T, "The key glycolytic enzyme phosphofructokinase is involved in resistance to antiplasmodial glycosides." mBio. 11, 6. e02842-20 (2020).
https://digitalcommons.wustl.edu/open_access_pubs/10825

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
The Key Glycolytic Enzyme Phosphofructokinase Is Involved in Resistance to Antiplasmodial Glycosides


ABSTRACT Plasmodium parasites rely heavily on glycolysis for ATP production and for precursors for essential anabolic pathways, such as the methylerythritol phosphate (MEP) pathway. Here, we show that mutations in the Plasmodium falciparum glycolytic enzyme, phosphofructokinase (PfPKF9), are associated with in vitro resistance to a primary sulfonamide glycoside (PS-3). Flux through the upper glycolysis pathway was significantly reduced in PS-3-resistant parasites, which was associated with reduced ATP levels but increased flux into the pentose phosphate pathway. PS-3 may directly or indirectly target enzymes in these pathways, as PS-3-treated parasites had elevated levels of glycogenic and tricarboxylic acid (TCA) cycle intermediates. PS-3 resistance also led to reduced MEP pathway intermediates, and PS-3-resistant parasites were hypersensitive to the MEP pathway inhibitor, fosmidomycin. Overall, this study suggests that PS-3 disrupts core pathways in central carbon metabolism, which is compensated for by mutations in PfPKF9, highlighting a novel metabolic drug resistance mechanism in P. falciparum.

IMPORTANCE Malaria, caused by Plasmodium parasites, continues to be a devastating global health issue, causing 405,000 deaths and 228 million cases in 2018. Understanding key metabolic processes in malaria parasites is critical to the development of new drugs to combat this major infectious disease. The Plasmodium glycolytic pathway is essential to the malaria parasite, providing energy for growth and replication and supplying important biomolecules for other essential Plasmodium anabolic pathways. Despite this overreliance on glycolysis, no current drugs target glycolysis, and there is a paucity of information on critical glycolysis targets. Our work addresses this unmet need, providing new mechanistic insights into this key pathway.

KEYWORDS Plasmodium falciparum, drug resistance mechanisms, drug targets, glycolysis, metabolic regulation

The parasite Plasmodium falciparum is the major cause of malaria-associated mortality, with an estimated 405,000 deaths reported in 2018 (1). Unfortunately, there is no broadly effective malaria vaccine, and increasing resistance to current antimalarials is driving the search for new targets for antimalarial drug development (1, 2). The malaria parasite has a complex life cycle, with the asexual intraerythrocytic stage being the cause of the clinical manifestations associated with this disease. During this stage,
the malaria parasite relies heavily on glycolysis for ATP energy production, with glucose consumption increasing 100-fold in *P. falciparum*-infected erythrocytes (3). The first rate-limiting and regulatory step in the glycolytic pathway is the conversion of fructose-6-phosphate to fructose-1,6-biphosphate (FBP) by the enzyme phosphofructokinase (PFK). The *P. falciparum* genome contains two ATP-dependent PFK genes, *Pfpfk9* and *Pfpfk11* (PF3D7_0915400; chromosome 9 [4]) encodes a 160-kDa protein containing fused \( H9252 \) and \( H9251 \) domains that is structurally similar to plant PFKs and has low amino acid similarity to human PFKs (\( H11011 \) 15%) (5). *Pfpfk9* has been shown to encode a catalytically active PFK enzyme (5) and appears to be essential (6). In contrast, *Pfpfk11* (PF3D7_1128300; chromosome 11 [4]) appears to be dispensable in asexual-stage *P. falciparum* (6).

In recent work, *PfPFK9* mutations have been associated with the reversal of fosmidomycin resistance in *P. falciparum* (7). Fosmidomycin, an antibiotic and antimalarial drug candidate, acts as a competitive inhibitor of a key enzyme in methylerythritol phosphate (MEP) pathway isoprenoid biosynthesis in the apicoplast of the malaria parasite (8). Fosmidomycin resistance has been linked to the functional loss of haloacid dehalogenase 1 (*PfHAD1*), a sugar phosphatase (9). In fosmidomycin-resistant parasites, loss of *PfHAD1* function results in dysregulation of glycolysis and increased flux of triose-phosphates into the MEP pathway, with a concomitant reduction in the effectiveness of fosmidomycin (9). A second HAD family member, *PfHAD2*, has also been implicated in fosmidomycin resistance (7). Curiously, fosmidomycin sensitivity is restored in *PfHAD2* mutants that have been subjected to prolonged culture in the absence of drug pressure. These *PfHAD2* mutants gain mutations in *PfPFK9* that result in the restoration of fosmidomycin sensitivity (7).

In this study, we provide the first report that *PfPFK9* mutations are associated with resistance to an antiplasmodial compound. Previously, we screened a panel of primary sulfonamide glycosides for *in vitro* growth inhibitory activity against asexual intraerythrocytic stages of drug-sensitive (3D7) and multidrug-resistant (Dd2) *P. falciparum* parasites. The most potent sulfonamide glycoside (PS-3) exhibited a 50% inhibitory concentration (IC\(_{50}\)) value of \(~1\) \( \mu \)M and >40-fold selectivity for *P. falciparum* versus that for mammalian cells (Fig. 1) (10). In this study, *P. falciparum* parasites were selected for *in vitro* resistance to PS-3 (10), followed by whole-genome sequence analysis of clones to identify putative PS-3 targets and/or resistance mechanisms. A point mutation in the *PfPFK9* gene was shown to be linked to PS-3 resistance and subsequently confirmed via reverse genetics. While PS-3 did not significantly inhibit recombinant *Plasmodium* PFK activity, PS-3-resistant *P. falciparum* parasites with *PfPFK9* gene mutations redirected glucose flux into the pentose phosphate pathway, at the expense of upper glycolysis, while still maintaining lower glycolysis and continued ATP production. While the precise target of PS-3 remains undefined, these data suggest that the
redirection of carbon fluxes into the pentose phosphate pathway, mediated by mutations to PfPFK9, confers resistance to this novel antimalarial compound.

RESULTS

Generation of PS-3-resistant *P. falciparum* clones. A *P. falciparum* 3D7 clone was generated by limiting dilution (termed 3D7-C3) and used to generate PS-3-resistant parasites using a stepwise selection method, beginning at 1× IC₅₀ (1 μM). After ~80 asexual intraerythrocytic cycles, parasites were selected with the ability to grow in ~10× the *P. falciparum* 3D7 wild-type PS-3 IC₅₀ (~10 μM; termed 3D7-C₃PS₃) (Fig. 2A). In contrast, there was no significant difference in IC₅₀ values for the control drug chloroquine (p > 0.05) (Fig. 2B). The 3D7-C₃PS₃ line remained resistant to PS-3 following cryopreservation, thawing, and reculture (see Fig. S1A in the supplemental material), and this phenotype was stable after removal of PS-3 selection pressure for >10 weeks (Fig. S1B). Exposure of 3D7-C₃PS₃ parasites to higher concentrations of PS-3 (~20× IC₅₀...
TABLE 1 Activity of antiplasmodial compounds against *P. falciparum* 3D7-C3PS3 and 3D7-C3 parasites

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC$_{50}$ (µM)$^{a}$</th>
<th>3D7-C3 wild type</th>
<th>3D7-C3PS3</th>
<th>Ri$^{b}$</th>
<th>P value$^{c}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS-3</td>
<td>1.250 (± 0.640)</td>
<td>10.410 (± 1.380)</td>
<td>8.3</td>
<td>0.0006</td>
<td></td>
</tr>
<tr>
<td>Chloroquine</td>
<td>0.014 (± 0.003)</td>
<td>0.011 (± 0.004)</td>
<td>0.8</td>
<td>0.9142</td>
<td></td>
</tr>
<tr>
<td>Pyrimethamine</td>
<td>0.033 (± 0.010)</td>
<td>0.054 (± 0.028)</td>
<td>1.6</td>
<td>0.2826</td>
<td></td>
</tr>
<tr>
<td>Artesunate</td>
<td>0.004 (± 0.002)</td>
<td>0.004 (± 0.001)</td>
<td>1.0</td>
<td>0.6779</td>
<td></td>
</tr>
<tr>
<td>DSM161</td>
<td>0.345 (± 0.065)</td>
<td>0.359 (± 0.027)</td>
<td>1.0</td>
<td>0.7535</td>
<td></td>
</tr>
<tr>
<td>KAE609</td>
<td>0.0015 (± 0.0001)</td>
<td>0.0014 (± 0.0003)</td>
<td>0.9</td>
<td>0.5734</td>
<td></td>
</tr>
<tr>
<td>Atovaquone</td>
<td>0.0002 (± 0.0001)</td>
<td>0.0002 (± 0.0001)</td>
<td>1.0</td>
<td>0.5185</td>
<td></td>
</tr>
<tr>
<td>Cycloguanil</td>
<td>0.0103 (± 0.0004)</td>
<td>0.0141 (± 0.0002)</td>
<td>1.4</td>
<td>0.0001</td>
<td></td>
</tr>
<tr>
<td>Quinine</td>
<td>0.0224 (± 0.0013)</td>
<td>0.0133 (± 0.0003)</td>
<td>0.6</td>
<td>0.0101</td>
<td></td>
</tr>
</tbody>
</table>

$^{a}$Mean IC$_{50}$ (± SD) for three independent experiments, each in triplicate wells.

$^{b}$Ri, resistance index: IC$_{50}$ resistant line (3D7-C3PS3)/IC$_{50}$ wild-type line (3D7-C3). The higher the Ri the, higher the level of resistance.

$^{c}$Statistical difference between IC$_{50}$s was determined using an unpaired t test with GraphPad Prism data analysis software.

In vitro IC$_{50}$ values for 3D7-C3PS3 versus those for 3D7-C3 wild-type parasites showed generally no significant difference for the clinically used antimalarial drugs chloroquine, pyrimethamine, cycloguanil, artesunate, atovaquone, and quinine ($P > 0.05$) (Table 1). Likewise, there was no significant difference in IC$_{50}$ values for the clinical candidates KAE609 (11) (P-ATP4 inhibitor) and DSM161 (12) (an analogue of DSM265, a dihydroorotate reductase [DHOD] inhibitor [13]). This is reflected in the calculated resistance indices (Ri), which range from 0.8 to 1.6. In contrast, a Ri of 8.3 was obtained when comparing *P. falciparum* 3D7-C3 and 3D7-C3PS3 PS-3 IC$_{50}$ values (Table 1).

**Structure-activity relationship analysis of the *P. falciparum* PS-3 resistance phenotype.** To define which PS-3 structural group(s) contributes to the 3D7-C3PS3 resistance phenotype, PS-3 analogues were tested in *in vitro* growth inhibition assays against 3D7-C3 and 3D7-C3PS3 parasites. Compounds included PS-3', which lacks the primary sulfonamide (PS) moiety, and four compounds that retain the PS moiety (PS-1, PS-3, PS-7, and PS-10) (Table 2). All compounds contain a per-O-acetylated glucose type sugar with an acetyl R group and a triazole substituent (Y = I or H) but vary with respect to their glycosidic linkage (X = S, O, or SO$_2$) (Table 2). Compared to PS-3, the absence of the PS moiety in PS-3' resulted in a significant reduction in activity for both 3D7-C3PS3 and 3D7-C3 wild-type parasites (~4-fold higher IC$_{50}$; $P < 0.05$) (Table 2); however, the PS-3' Ri remained similar (Ri, ~6) (Table 2) to that for the PS-3 selection compound, indicating that the PS-3 resistance phenotype is independent of the PS group. Likewise, PS-7 and PS-10 showed a reduction in overall activity against both 3D7-C3PS3 and wild-type 3D7-C3 but retained similar Ri values to that for PS-3 (Ri ~6 to 7) (Table 2), indicating that the variable glycosidic linkage (X = S, O, or SO$_2$) (Table 2) does not impact resistance to PS-3. PS-1, which is identical to PS-3 (Table 2) (Y = I) except for the triazole substituent (Table 2) (Y = H) showed >2.3-fold reduced activity against 3D7-C3PS3 versus that against 3D7-C3, suggesting that the iodo substituent (Y = I) of the triazole moiety is likely also not contributing to the resistance phenotype of 3D7-C3PS3 parasites. Overall, these structure-activity relationship (SAR) data implicate the glucose moiety in PS-3 as being associated with the resistance phenotype of 3D7-C3PS3 parasites.

To determine if sugars other than glucose play a role in the 3D7-C3PS3 resistance phenotype, PS-3 analogues differing only with respect to the sugar group were tested against 3D7-C3PS3 and 3D7-C3. 3D7-C3PS3 was found to be cross resistant to PS-11 (galactose replacing glucose) and PS-12 (glucuronic acid replacing glucose), as shown by similar Ri values to that for PS-3 (Table 2). To a lesser extent, 3D7-C3PS3 was found to be cross resistant to PS-14 (the disaccharide maltose replacing glucose; Ri, 2.5)
Together, these SAR data suggest that the mode of action of PS analogues containing the sugars glucose, galactose, glucuronic acid, and, to a lesser extent, maltose may be affected by the phenotypic change associated with the 3D7-C3PS3 resistance. These sugars have subtle structural and stereochemical differences. Interestingly, 3D7-PfHK/H11001, a parasite line that was previously shown to be resistant to the glucose analogue 2-deoxyglucose (14), is not resistant to PS-3 (data not shown).

Whole-genome sequencing of 3D7-C3PS3 subclones identifies two independent single nucleotide polymorphisms in the P. falciparum phosphofructokinase (PfPFK) gene. Three independent 3D7-C3PS3 subclones were generated (termed 3D7-C3PS3-1, 3D7-C3PS3-2, and 3D7-C3PS3-3), and their PS-3 resistance profiles were confirmed (Fig. 2C). The IC50 values of all the clones were significantly different from that of the wild-type 3D7-C3 parasites (Fig. 2C) (P < 0.05) but not for the control drug chloroquine (P > 0.05) (Fig. 2D). PS-3 resistance indices of 15.0, 6.6, and 10.8 were observed for 3D7-C3PS3-1, 3D7-C3PS3-2, and 3D7-C3PS3-3, respectively. A comparison of the genome sequences of the three clones versus that for 3D7-C3 revealed 12 new coding mutations, which included two point mutations (L513Q and R860G) in the PfPFK9 gene (PF3D7_0915400) (Fig. 3; Table S1). The L513Q mutation was found only in clone 3D7-C3PS3-2 and maps to the β-domain of PfPK9 (amino acids 1 to 660) (Fig. 3). The R860G mutation was found in clones 3D7-C3PS3-1 and 3D7-C3PS3-3 and maps to the α-domain (amino acids 777 to 1418) (Fig. 3). Mutations were observed in the P. falciparum multidrug-resistant protein 2 (PFMDR2; PF3D7_1447900) and the P. falciparum sodium/hydrogen exchanger (PFNHE; PF3D7_1303500) for the 3D7-C3PS3-1 and 3D7-C3PS3-3 clones (Table S1). The likelihood of finding three independent missense mutations in PfPK9 by chance is very low (P = 1.7e−10, hypergeometric mean function). Furthermore, in contrast to that for PFMDR2, no PfPK9 mutations were detected in a systematic analysis of the genome sequences of 262 evolved parasites resistant to 37 diverse compounds (15) performed with the same sequence analysis pipeline. No other common gene amplifications were observed in the three independent clones analyzed.

### TABLE 2

*In vitro* activity of PS glycoside analogues against *P. falciparum* 3D7-C3PS3 and 3D7-C3 parasites

<table>
<thead>
<tr>
<th>Compound</th>
<th>PS present</th>
<th>Structural feature</th>
<th>IC50 (µM)</th>
<th>3D7-C3</th>
<th>3D7-C3PS3</th>
<th>Ri</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PS-3</td>
<td>Yes</td>
<td>Glucose Ac I S</td>
<td>1.25 (±0.64)</td>
<td>10.41 (±1.38)</td>
<td>8.3</td>
<td>0.0006</td>
<td></td>
</tr>
<tr>
<td>PS-3'</td>
<td>No</td>
<td>Glucose Ac I S</td>
<td>6.42 (±1.43)</td>
<td>38.73 (±2.40)</td>
<td>6.0</td>
<td>0.0003</td>
<td></td>
</tr>
<tr>
<td>PS-7</td>
<td>Yes</td>
<td>Glucose Ac I SO2</td>
<td>9.08 (±2.70)</td>
<td>65.53 (±4.90)</td>
<td>7.2</td>
<td>0.0351</td>
<td></td>
</tr>
<tr>
<td>PS-10</td>
<td>Yes</td>
<td>Glucose Ac I O</td>
<td>5.15 (±1.42)</td>
<td>31.56 (±18.53)</td>
<td>6.1</td>
<td>0.1420</td>
<td></td>
</tr>
<tr>
<td>PS-11</td>
<td>Yes</td>
<td>Gal Ac I S</td>
<td>5.03 (±2.50)</td>
<td>22.40 (±7.90)</td>
<td>4.5</td>
<td>0.0219</td>
<td></td>
</tr>
<tr>
<td>PS-12</td>
<td>Yes</td>
<td>GlcOMe Ac I S</td>
<td>4.13 (±2.36)</td>
<td>19.62 (±6.95)</td>
<td>4.8</td>
<td>0.0217</td>
<td></td>
</tr>
<tr>
<td>PS-15</td>
<td>Yes</td>
<td>Mal Ac I S</td>
<td>3.14 (±0.97)</td>
<td>7.83 (±0.85)</td>
<td>2.5</td>
<td>0.0032</td>
<td></td>
</tr>
<tr>
<td>PS-1</td>
<td>Yes</td>
<td>Glucose Ac H S</td>
<td>43.19 (±9.04)</td>
<td>&gt;100.00</td>
<td>&gt;2.3</td>
<td>ND</td>
<td></td>
</tr>
</tbody>
</table>

**a**Gal, galactose; GlcOMe, glucuronic acid; Mal, maltose; Ac, acetate; H, hydrogen; I, iodine; S, sulfur; SO₂, sulfur dioxide; O, oxygen.

**b**Mean IC50 ± SD for three independent experiments each in triplicate wells.

**c**Ri, resistance index: IC50 resistant line (3D7-C3PS3)/IC50 wild-type line (3D7-C3). The higher the Ri, the higher the level of resistance.

**d**Statistical difference between IC50s was determined using an unpaired t test with GraphPad Prism data analysis software.
Modeling of glycoside resistance alleles. To inform the possible structural basis of compound resistance, we evaluated the effects of resistance alleles (R860G and L513Q) on three-dimensional models of \textit{PfPFK9}/H9251 and \textit{PfPFK9}/H9252 domains (Fig. 3). Currently, no structure exists for the distinct “long” PFKs observed in apicomplexans. Our structural model shows that the R860G and L513Q mutations do not share cognate regions of their respective domains. The R860G mutation is adjacent to the substrate-binding pocket of the C-terminal \(\alpha\)-domain, while the L513Q mutation is buried between an alpha-helix and beta-strand of the N-terminal \(\beta\)-domain and is not predicted to impact substrate-binding or catalytic residues. This suggests that these mutations may share their resistance phenotype through a more general mechanism of overall reduced PFK function rather than a specific change in a particular inhibitor-protein binding interface.

\textit{PfPFK9} R860G mutation validated as a resistance mechanism of PS-3. CRISPR/Cas9-based genome editing was used to validate the contribution of the two \textit{PfPFK9} mutations, L513Q and R860G, to the resistance phenotype. Donor templates were synthesized and cloned into a CRISPR vector encoding Cas9 and one of two single guide RNAs (sgRNAs) targeting the relevant locus (see Fig. S3). For each mutation, two donor templates were generated encoding either the putative resistance mutation (e.g., L513Q) or a silent control (e.g., L513L). Additional silent mutations common to both sets of donors were also included to prevent sgRNA binding to the repair locus (Fig. S3). The mutations were introduced into the Dd2 strain, and clonal lines were derived. The R860G-edited line demonstrated a 2.1-fold increase in IC\(_{50}\) values compared to that for the R860 silent control (\(P < 0.0001\)) (Fig. 2E). There was no significant change in IC\(_{50}\) values for the L513Q-edited line compared to that for the L513 silent control (\(P > 0.05\)) (Fig. 2F), which may possibly be due to the different genetic background (Dd2 versus 3D7) or the contribution of additional alleles. These data, nevertheless, provide evidence of an association between the \textit{PfPFK9} R860G mutation and \textit{P. falciparum} resistance to PS-3.

Mutations in \textit{PfPFK9} lead to changes in central carbon metabolic flux. To investigate the impact of nonsynonymous mutations in \textit{PfPFK} on parasite metabolism, \(^{13}\text{C}\)-glucose labeling studies were undertaken on 3D7-C3\(^{P53-1}\) and 3D7-C3\(^{P53-3}\) (both
containing the R860G mutation). Erythrocytes infected with trophozoite-stage parasites were labeled with \(^{13}\text{C}\)-glucose (present in medium at a 1:1 ratio with \(^{12}\text{C}\)-glucose) for 30 min, and incorporation into a wide range of intermediates in central carbon metabolism was quantitated by liquid chromatography-mass spectrometry (LC-MS). The pool sizes of several glycolytic intermediates immediately downstream of Pf\(PFK\), including fructose-1,6-bisphosphate and dihydroxyacetone phosphate (DHAP), were significantly reduced in the mutant lines, whereas those of several nucleoside mono- and diphosphates were elevated (Fig. 4A). The level of \(^{13}\text{C}\) enrichment in these downstream intermediates was also greatly reduced, suggesting that the metabolic flux through PFK was severely compromised in 3D7-C3PS3-1 and 3D7-C3PS3-3-infected erythrocytes (Fig. 4B). Reduced flux through the reversible aldolase reaction was further supported by the markedly reduced levels of \(^{+3}\labeled\)-fructose-1,6-bisphosphate in the mutant lines, which reflects the rate of interconversion of DHAP/glyceraldehyde-3-phosphate (GAP) and fructose-1,6-bisphosphate. These labeling studies indicate that mutations acquired in 3D7-C3PS3-1 and 3D7-C3PS3-3 parasites lead to reduced Pf\(PFK\) activity. Interestingly, \(^{13}\text{C}\) enrichment in GAP, an intermediate in both glycolysis and the pentose phosphate pathway (PPP), was unaltered in 3D7-C3PS3-1 and 3D7-C3PS3-3 parasites, while labeling of several intermediates in the oxidative and nonoxidative PPP (sedoheptulose-7-P and ribose-5-P) was increased in these mutant lines. These data strongly suggest that partial loss of Pf\(PFK\) activity leads to rerouting of carbon flux through the PPP, leading to the production of GAP that can still be catabolized in lower glycolysis. This bypass would allow ATP-producing steps in lower glycolysis to proceed, albeit at a reduced rate, as evidenced by the lower levels of synthesis of phosphoenolpyruvate (PEP) and lactate (Fig. 4B). The reduction of glycolytic flux in 3D7-C3PS3-1 and 3D7-C3PS3-3 was consistent with an approximate 25% reduction in extracellular lactate secretion (Fig. 4B). The rerouting of carbon flux through the PPP, at the expense of glycolysis, would be expected to come with a fitness disadvantage as a result of reduced ATP production. This hypothesis was supported by the significant increase in ADP and AMP levels in the mutant lines, leading to reduced ATP/ADP and ATP/AMP ratios (Fig. 4A). Glycolysis is also the source of precursors for a number of anabolic pathways, such as isoprenoid biosynthesis, which uses phosphoenolpyruvate and DHAP generated downstream of PFK. Lastly, the isoprenoid biosynthetic intermediates deoxyribose-1-phosphate (DOXP) and methylerythritol-cyclo-pyrophosphate (MEcPP) were significantly reduced in both 3D7-C3PS3-1 and 3D7-C3PS3-3, indicating reduced flux into this pathway and an additional fitness disadvantage to PFK mutations (Fig. 4C).

**3D7-C3PS3 subclones display slowed in vitro growth compared to that of wild-type 3D7-C3 parasites.** To assess in vitro growth dynamics of P5-3-resistant parasites, the in vitro growth profiles of 3D7-C3PS3-1 and 3D7-C3PS3-3, compared to that of wild-type 3D7-C3 parasites, were examined by comparing growth over 72 h commencing at \(\sim3\) to 6 h postinvasion (see Fig. S4). No significant difference in parasitemia was seen up to 30 h postinvasion for 3D7-C3PS3-1 and 3D7-C3PS3-3 compared to that for 3D7-C3. In contrast, at 51 to 54 h and 75 to 78 h postinvasion, a >2-fold reduction in total parasitemia was observed for both 3D7-C3PS3 subclones compared to that of the wild type (\(P < 0.05\) and \(P < 0.01\), respectively) (Fig. S4). Upon examination of each developmental stage, no significant difference was seen in the percentages of each stage (early rings, mid/late rings, early/mid trophozoites, late trophozoites/early schizonts, and late schizonts) up to 30 h postinvasion for 3D7-C3 versus those for 3D7-C3PS3-1 and 3D7-C3PS3-3 (\(P > 0.05\)) (see Fig. S5A and B). However, at 51 to 54 h postinvasion, 2-fold reductions were seen in the percentages of rings for 3D7-C3PS3-1 and early/mid trophozoites for 3D7-C3PS3-3 compared to those for 3D7-C3 (\(P < 0.05\)) (Fig. S5C). Additionally, at 72 to 78 h postinvasion, a 2-fold increase in the percentage of late trophozoite/early schizonts and a 5-fold decrease in the percentage of late schizonts was observed for both 3D7-C3PS3 subclones compared to those for the wild type (\(P < 0.01\) and \(P < 0.05\), respectively) (Fig. S5D). Overall, these data suggest that parasite growth is developmentally delayed in 3D7-C3PS3-1 and 3D7-C3PS3-3 parasites.
**FIG 4** Dynamic $^{13}$C-U-glucose labeling of PS-3-sensitive and -resistant trophozoite-stage *P. falciparum*-infected erythrocytes. Purified ($\approx$95%) trophozoite-stage *P. falciparum*-infected erythrocytes were incubated in RPMI 1640 medium containing a 1:1 mixture of $^{12}$C/$^{13}$C$_6$-glucose (11 mM) and collected for LC-MS analysis across a 30-min time course. (A) Total metabolite pools were monitored over the time course and are expressed as the log$_2$ ratio of the 3D7-C3 PS3-1 or 3D7-C3 PS3-3 to the wild-type parental strain. (B) The rate of $^{13}$C incorporation into glycolytic and pentose phosphate pathway intermediates. The y axis represents the amount of fully labeled metabolite as the estimated intracellular concentration (with the exception of fructose-1,6-bisphosphate which depicts both the forward [M]$_6$ and backward [M]$_3$ species). The data presented in panels A and B represent the averages from three biological replicates (± standard errors of the means [SEMs]) and the excreted lactate data from two biological replicates (±SDs). (C) The intracellular pool of the isoprenoid biosynthetic intermediates in wild-type (WT) and 3D7-C3 PS3-1 or 3D7-C3 PS3-3 purified infected erythrocytes. The total pool sizes of deoxyribose-1-phosphate (DOXP), methylerythritol-cyclopropyl phosphate (MEcPP), and isopentyl-1-phosphate (IPP) are presented as arbitrary ion counts (normalized for data acquisition and degradation across different days), and represent three biological replicates performed on different days (means ± SEMs). One-way analysis of variance (ANOVA) testing was performed to test statistical significance. *, P < 0.05.
Metabolite profiling of 3D7-infected red blood cells treated with PS-3. To investigate whether PfpK is a direct target of PS-3 or if mutations in PfpK provide a metabolic bypass that indirectly confers resistance, erythrocytes infected with purified trophozoite-stage P. falciparum 3D7 were treated with PS-3 (40 μM PS-3 (2 h). Mass-to-charge (m/z) features were aligned and a pairwise comparison performed between PS-3-treated and untreated purified infected erythrocytes using a P value of <0.05 (FDR corrected) and fold change of 2 cutoffs for determining significant peaks. Data are presented as the mean ratios from four independent replicates. Putative metabolite identifications were made via the METLIN database and confirmed with authentic standards (highlighted yellow).

**FIG 5** Metabolite perturbations following exposure to PS-3. Untargeted metabolite profiling of purified trophozoite-stage parasite-infected erythrocytes treated with 40 μM PS-3 (2 h). Mass-to-charge (m/z) features were aligned and a pairwise comparison performed between PS-3-treated and untreated purified infected erythrocytes using a P value of <0.05 (FDR corrected) and fold change of 2 cutoffs for determining significant peaks. Data are presented as the mean ratios from four independent replicates. Putative metabolite identifications were made via the METLIN database and confirmed with authentic standards (highlighted yellow).

Metabolite profiling of 3D7-infected red blood cells treated with PS-3. To investigate whether PfpK is a direct target of PS-3 or if mutations in PfpK provide a metabolic bypass that indirectly confers resistance, erythrocytes infected with purified trophozoite-stage P. falciparum 3D7 were treated with PS-3 (40 μM; equivalent to 4 x IC50 for this parasite life cycle stage at 48 h of exposure) for 2 h, and changes in metabolite levels determined using untargeted LC-MS profiling (Fig. 5). More than 90 of the 3,327 detected mass-to-charge (m/z) features were significantly different (P < 0.05, false-discovery rate [FDR] corrected) between those treated with PS-3 and the untreated control. The METLIN database was queried for possible identities using the M-H criteria with a mass tolerance of 10ppm (assuming that metabolites existing as other adducts will also be present as the M-H adduct). Several features corresponded to glycolytic intermediates, and these were subsequently verified using authentic standards (Fig. 5, highlighted in yellow). In particular, lactate and pyruvate were significantly increased following PS-3 treatment, with glycerate and the tricarboxylic acid (TCA) cycle-linked intermediates 2-oxoglutarate and 2-hydroxyglutarate also significantly elevated. This metabolic phenotype is distinct from that observed in the PS-3-resistant lines, indicating that PS-3 does not directly target PFK but inhibits other steps in central carbon metabolism that are compensated for by rerouting of glucose into the pentose phosphate pathway and/or reduced flux in lower glycolysis.

Antiplasmodial glycosides do not directly inhibit apicomplexan phosphofructokinases. To further evaluate whether PfpK9 represents the direct target of antiplasmodial glycosides, we evaluated compound sensitivity against P. falciparum and Plasmodium knowlesi PFK9. While we, and others, have not been able to purify full-length PfpK9 (5), P. falciparum and P. knowlesi αβ domains readily express as active individual domains (see Fig. S6). We screened each recombinant protein for enzymatic inhibition at a single compound concentration (50 μM) (Fig. 6A), revealing possible modest inhibition of purified PfpKβ by compounds PS-3 and PS-12. However, dose-responsive inhibition of PfpKβ confirmed little to no enzymatic inhibition by these compounds at concentrations similar to the compound’s cellular inhibition values (biochemical IC50 as follows: PS-3, >22 ± 4.33 μM; PS-12, >21 ± 1.49 μM) (Fig. 6B). The lack of direct inhibition of any domain of these PfpK enzymes suggests PfpK9 may not be the direct target of PS-3.
**PPFK mutants are not resistant to *Plasmodium* lactate transporter inhibitors.**

The increases observed in the lower glycolytic intermediates lactate, pyruvate, and glycerate in PS-3-treated trophozoites raised the possibility that PS-3 may act by blocking lactate efflux across the parasite plasma membrane. The *Plasmodium* formate nitrite transporter (*PfFNT*) mediates the efflux of lactate from the malaria parasite (16, 17), and two malaria box compounds (MMV007839 and MMV000972) were recently shown to inhibit lactate transport via inhibition of *PfFNT* (18). To further investigate if PS-3 targeting is related to *PfFNT* inhibition, the *PfPFK R860G* and *L513Q* mutant parasites were screened against MMV007839 and MMV000972 in 72-h growth inhibition assays. No significant difference (P > 0.05) was observed in IC50 values for each compound against both the mutant and silent control lines (MMV 007839: R860G IC50, 0.13 ± 0.01 μM; R860 silent IC50, 0.15 ± 0.02 μM; MMV 000972: R860G IC50, 0.76 ± 0.08 μM; R860 silent IC50, 0.81 ± 0.12 μM; MMV 007839: L513Q IC50, 0.13 ± 0.06 μM; L513 silent IC50, 0.15 ± 0.03 μM; MMV 000972: L513Q IC50, 0.59 ± 0.27 μM; L513 silent IC50, 0.93 ± 0.16 μM) (see Fig. S7). This lack of cross-resistance suggests that PS-3 may not target *PfFNT*.

**PS-3-resistant clones are hypersensitive to fosmidomycin.**

Our metabolomic studies indicated that glycolytic flux is reduced in 3D7-C3PS3 subclones, which leads to decreased flux of glycolytic intermediates into the apicoplast isoprenoid DOXP biosynthetic pathway (Fig. 4C). Previous studies on the *PhAD1* mutants have shown that changes in glycolytic flux directly impact the resistance of asexual intraerythrocytic-stage *P. falciparum* to fosmidomycin (9), a potent competitive inhibitor of the apicoplast MEP pathway enzyme deoxyxylulose phosphate reductoisomerase (*PfDXR*) (19). We therefore assessed whether the observed decrease in glycolytic flux in the PS-3-resistant lines was associated with increased sensitivity to fosmidomycin in 72-h growth inhibition assays. A significant increase in activity for fosmidomycin was seen for all three 3D7-C3PS3 clones compared to that for the 3D7-C3 wild-type parasites (Fig. 7A)
As previously observed (Fig. 2C), PS-3 showed a significant decrease in activity for all three 3D7-C3PS3 clones compared to the that for 3D7-C3 (Fig. 7B) (7- to 15-fold lower IC$_{50}$; $P < 0.001$). The PS-3-resistant parental line (3D7-C3PS3) also displayed hypersensitivity to the *P. falciparum* apicoplast inhibitor clindamycin (see Fig. S8) (3-fold higher IC$_{50}$ values for 3D7-C3 compared to that for 3D7-C3PS3; $n = 2$). Collectively, these data support the hypothesis that resistance to PS-3 in the 3D7-C3PS3 clones is associated with metabolic adaptation that leads to decreased availability of glycolytic intermediates for anabolic pathways, such as isoprenoid biosynthesis.

**Increased glycolytic flux may also result in resistance to PS-3.** To further investigate the mode of action of PS-3 and potential resistance mechanisms, we investigated the sensitivity of the *P. falciparum* had1 mutant, AM1, to PS-3. The *Pfhad1* gene encodes a haloacid dehalogenase that dephosphorylates a range of glycolytic intermediates in vitro and appears to be involved in negatively regulating glycolytic flux. Loss-of-function mutations in *Pfhad1* are associated with increased flux of glycolytic intermediates into isoprenoid synthesis and resistance to fosmidomycin (9). The AM1 parasite line exhibited a 5-fold increase in resistance to PS-3 compared to that of the parental 3D7 line ($P < 0.001$) (Fig. 8A). This level of resistance is comparable to that exhibited by the AM1 line to fosmidomycin (i.e., 4-fold increase in IC$_{50}$; $P < 0.05$) (Fig. 8B). This finding suggests that global changes in central carbon metabolism that can be associated with either an increase in glycolytic flux (as occurs in AM1) or a decrease in glycolytic flux (as occurs in the 3D7-C3PS3 subclones) increase the resistance of asexual stages to PS-3. However, unlike the control fosmidomycin, the antiplasmodial activity of PS-3 was not rescued by supplementation with isoprenoid isopentenyl pyrophosphate (IPP) (see Fig. S9). Furthermore, we find that PS-3 does not directly inhibit *PfHAD1* or *PfHAD2* enzyme activity in vitro (Fig. 9). Together, these data strongly show that PS-3 has a distinct mechanism of action from other direct MEP pathway inhibitors, such as fosmidomycin.
DISCUSSION

Malaria remains a major global concern with efforts to control this disease being hampered by parasite drug resistance and the lack of a broadly effective vaccine (1). Although there are several new chemotherapeutics in various stages of preclinical or clinical development, most of these have previously exploited targets or are reformulations or different combinations of existing antimalarial drugs (20). Therefore, strategies to identify new antimalarial drug targets and antiplasmodial chemotypes that have novel modes of action are crucial. Fortunately, recent reductions in the cost of whole-genome sequencing and the development of comprehensive global metabolomic profiling approaches have begun to yield some exciting progress in the antimalarial target identification arena. When combined with the selection of drug-resistant *P. falciparum* lines, this approach has resulted in the identification of new antimalarial targets and resistance mechanisms (11, 21, 22).

In this study, *in vitro* resistance selection was utilized to generate *P. falciparum* parasites resistant to an antiplasmodial glycoside (PS-3) (10). Importantly, PS-3-resistant parasites displayed no *in vitro* resistance to several clinically used antimalarial drugs or to two compounds that represent chemical classes under clinical development (11, 12), suggesting a novel mode of action/resistance. Historically, the PS moiety is known to inhibit carbonic anhydrase (CA) enzyme activity in many organisms (23), including *P. falciparum* (24, 25). In this study, we demonstrate that PS-3 resistance in *P. falciparum* is not linked to the PS moiety, as no change in the resistance profile was observed for PS-3', the non-PS structural analogue of PS-3 (Table 2). Further screening of PS glycoside analogues against PS-3-resistant parasites revealed that the glucose component of PS-3 may be contributing to the resistance phenotype. These data support genome sequencing data of 3D7-C3PS3 clones and subsequent validation using reverse genetics, which indicate that the point mutation (R860G) in *PfPFK9*, the gene that encodes an isoform of the glycolytic enzyme phosphofructokinase, contributes to PS-3 resistance. However, the resistance index of the R860G-edited line was lower than that observed for the 3D7-C3PS3-1 and 3D7-C3PS3-3 clones (RI ~2.1, 10.8, and 15, respectively). This may be attributed to mutations in the *P. falciparum* multidrug-resistant protein 2 (*PfMDR2*; *Pf3D7_1447900*) and/or the *P. falciparum* sodium/hydrogen exchanger (*PfNHE; Pf3D7_1303500*), observed in the 3D7-C3PS3-1 and 3D7-C3PS3-3 clones only (see Table S1 in the supplemental material). The role of *PfMDR2* in antimalarial drug resistance is unclear, with some weak evidence linking resistance to pyrimethamine (26) and sulfadoxine (27) treatments. Likewise, there are contradictory reports on the association of sequence polymorphisms in the *PfNHE* gene and quinine resistance (28-31). In this study, the 3D7-C3PS3 parasites were not resistant to pyrimethamine and quinine (Table 1); however, the *PfMDR2* and *PfNHE* mutations observed in the 3D7-C3PS3-1 and 3D7-C3PS3-3 clones were not reported previously; therefore, further studies are required to confirm if these mutations are associated with resistance to PS-3. While mutations in *PfMDR2* and *PfNHE* genes may be contributing to PS-3 resistance, this is more likely to be via nonspecific multidrug resistance mechanisms (32, 33). On the other hand, the PFK enzyme has an essential housekeeping role in *P. falciparum* central carbon metabolism; therefore, mutations in this gene are more likely to be target associated. Surprisingly, the LS13Q-edited line was not resistant to PS-3, and the 3D7-C3PS3-2 clone containing this mutation did not share any other common mutations with the other two clones (Table S1). In this case, it is possible that multiple background mutations (Table S1) are contributing to the resistance profile of the 3D7-C3PS3-2 clone and masking the effect that the LS13Q mutation may be exhibiting. Alternatively, our modeling suggests that the LS13Q mutation may have less of an effect on *PfPFK* function due to its more distal proximity to the substrate-binding pocket than the R860G mutation (Fig. 3). It should also be noted that the LS13Q clone reported in this study is a subclone of the original LS13Q clone generated. This original clone did display resistance to PS-3 (~6-fold increase in IC50 [n = 1] for two independent PS-3 stocks; data not shown). However, this phenotype was lost following cryopreservation,
and a reversion to the wild-type genotype was observed. It is therefore conceivable that the L513Q subclone may have gained mutations in another region of the genome that may have restored sensitivity to PS-3. Nonetheless, overall, these data strongly suggest that the \textit{Pf} \textit{PFK} R860G mutation contributes to PS-3 resistance, suggesting that alterations in glycolytic flux help to bypass the mode of action of PS-3.

To further understand the impact that the R860G \textit{Pf} \textit{PFK} mutation has on \textit{P. falciparum} metabolism, $^{13}$C-glucose fluxes were measured in both the PS-3-resistant clones (3D7-C3PS3-1 and 3D7-C3PS3-3) and 3D7-C3 wild-type parasites. These studies revealed a profound rewiring of glucose fluxes in the two resistant clones. In particular, a reduction in labeling of intermediates immediately downstream of PFK was associated with increased flux of $^{13}$C-glucose into the PPP (Fig. 4). The redirection of glucose-6-phosphate into the PPP likely accounts for the reduction of ATP/ADP and ATP/AMP ratios and reduced \textit{in vitro} growth of PS-3-resistant parasites (Fig. S4). On the other hand, increased flux into the PPP would allow regeneration of NADPH and contribute to a more robust redox state. Surprisingly, our data suggest that PPK may not be the direct target of PS-3, as PS-3 was unable to inhibit recombinant PPK and \textit{P. knowlesi} PPK (PKPK) enzymes (Fig. 6). Furthermore, \textit{in silico} homology modeling predicts that PS-3 is not likely to affect PFK substrate binding or catalysis. Nonetheless, it should be noted that PS-3 was only tested against the individual subunits of PPK, as no full-length enzyme is available; thus, we cannot completely rule out PPK as a target of PS-3. However, PS-3 could in principle inhibit another enzyme in the glycolytic pathway or in the pentose phosphate pathway. Initially, we hypothesized that PS-3 may inhibit the parasite’s lactate transporter (\textit{P. falciparum} formate nitrite transporter, or \textit{Pf}FNT, a validated drug target [16, 17]), resulting in a toxic buildup of metabolites. This would be consistent with the increases seen in the lower glycolytic intermediates (lactate, pyruvate, and glyceral) in PS-3-treated trophozoites (Fig. 10). PS-3-resistant parasites may overcome this toxicity by redirecting glycolytic flux away from lower

![Diagram](https://journals.asm.org/journal/mbio.on/24.Sep.2021)
glycolysis, resulting in less lactate being excreted and hence reducing the potency of PS-3. However, the L513Q and R860G mutant parasites were not cross resistant to the PfFNT inhibitors MMV000972 and MMV007839 (18) (Fig. S7). Moreover, the elevation of pyruvate and lactate following PS-3 treatment is consistent with PfFNT inhibition, but PS-3 treatment does not lead to the additional perturbations reported for PfFNT inhibition (e.g., pyrimidine biosynthesis and hemoglobin catabolism [18]). However, it is possible that differences in lactate accumulation may exist between P跌幅7 and P跌幅2, warranting PfFNT inhibition studies against the 3D7 PS-3-selected clones. To the best of our knowledge, there are no reports comparing 3D7 and Dd2 lactate metabolism, but we do know that 3D7 lactate metabolic profiles are similar to the profiles of other multidrug-resistant strains 7G8 and K1 (34) and a P跌幅7 chloroquine-resistant transporter (PFCRT) mutant line (35). Therefore, while we cannot completely discount the possibility that PS-3 may partially block PfFNT, with the evidence presented, we think another target is leading to the observed disruptions and eventual cell death. For example, PS-3 may inhibit an enzyme in the PPP, accounting for the accumulation of intermediates in glycolysis (glucose-6-P, pyruvate, lactate) and the TCA cycle (2-oxoglutarate and 2-hydroxyglutarate). In this case, PS-3-resistant parasites may have adapted by diverting the glycolytic intermediates (fructose-6-phosphate [F6P] and GAP) into the nonoxidative arm of the pentose phosphate pathway to overcome the effects of PS-3 (Fig. 10). In P. falciparum, the nonoxidative reactions of the PPP are mainly designed to produce ribose-5-phosphate (R5P) for nucleic acid synthesis. The nonoxidative arm of the PPP can also utilize the glycolytic intermediates (F6P and GAP) to produce R5P and vice versa (36). Two key enzymes involved in these processes are glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase (PGFluPho) (37) and transketolase (38), both of which have been characterized, are essential for asexual growth (6, 37), and differ structurally from their human homologues (37, 38), making them potential drug targets. Finally, it is possible that PS-3 may target other processes that lead to increased oxidative stress or loss of redox balance, such as mitochondrial metabolism, which is compensated for by increased flux through the PPP (with concomitant regeneration of NADPH).

In addition to reduced glycolytic flux, we also observed a reduction in the MEP pathway metabolites (DOXP, MECPP, and IPP) in PS-3-resistant parasites (Fig. 10). The MEP pathway is essential for the synthesis of isoprenoids in P. falciparum (39) and is dependent on the continuous import of glycolytic intermediates from the cytoplasm (9). The lead antimalarial drug fosmidomycin targets the MEP pathway enzyme, deoxyxylulose phosphate reductoisomerase (DXR), and fosmidomycin resistance has been linked to mutations in P. falciparum haloacid dehalogenases (P跌幅HAD1/2) (7, 9). While we found that fosmidomycin-resistant parasites (Fos' AM1 P跌幅HAD1 mutant) were also resistant to PS-3, the activity of PS-3 was not able to be rescued by IPP (isoprenoid precursor), and PS-3 did not inhibit Plasmodium HAD1/HAD2 recombinant enzymes. This suggests that PS-3 has a different mechanism of action/resistance to fosmidomycin. In contrast, PS-3-resistant parasites were found to be hypersensitive to fosmidomycin. Given that fosmidomycin targets DXR, it is likely that the reduction in DXR's substrate (DOXP) in PS-3-resistant parasites, coupled with a decrease in MECPP and IPP, results in an increase in fosmidomycin activity. Increased sensitivity to fosmidomycin has also been reported in P. falciparum parasites lacking phosphoglycerate phosphatase (PGP) (40). PGP, a third member of the P. falciparum HAD family, has been shown to be involved in regulating glycolysis and PPP flux in asexual P. falciparum (40). In Δpgp parasites, the loss of PGP leads to the inhibition of the PPP enzyme 6-phosphogluconate dehydrogenase (6-PGD), resulting in reduced glycolytic flux and causing reduced isoprenoid biosynthesis and increased sensitivity to fosmidomycin (40). Interestingly, fosmidomycin-resistant parasites harboring mutations in PfHAD2 display the opposite metabolomic profile to that of PS-3-resistant parasites. As mentioned above, PS-3-resistant parasites exhibit decreased levels of the metabolites FBP, DOXP, and MECPP, whereas a reported increase in these metabolites is seen in PfHAD2 mutants (7). In PfHAD2 mutants, the increase in FBP is thought to lead to the
increase of glycolytic intermediates into the MEP pathway, which results in an increase of MEP pathway metabolites, thus reducing the sensitivity to fosmidomycin (7). Furthermore, mutations in *PpFK9* have been shown to restore fosmidomycin sensitivity in these *PmAD2* mutant parasites (7); however, these mutations are not the same as those seen in PS-3-resistant parasites. Overall, these findings provide further evidence that *PpFK9* plays an important regulatory role in central carbon metabolism to modify drug sensitivity.

In this study, we identified a novel mechanism of *P. falciparum* drug resistance and have further highlighted the importance of the role of *PpFK9* in regulating central carbon metabolism to offset the effects of antiplasmodial compounds. While the specific molecular target of PS-3 remains unclear, it is promising that no cross-resistance exists with several of our clinically used antimalarials, indicating that this chemical class is likely to have a different mode of action from that of our current drugs. Furthermore, our PS-3-resistant parasites will provide a useful tool for studying central carbon metabolism in *P. falciparum* and aid in identifying other inhibitors of these pathways for development as antimalarial drug leads.

**MATERIALS AND METHODS**

**Compounds.** PS glycosides and matched control compounds were synthesized as previously reported by us (10). Chloroquine, artesunate, pyrimethamine, and cytochalasin B were purchased from Sigma-Aldrich, USA. DSM161 (12) was supplied by Margaret Philips from UT Southwestern, Dallas, TX, USA. Stock solutions were prepared in 100% dimethyl sulfoxide (DMSO; Sigma-Aldrich, USA), stored at -20°C and diluted as required.

**P. falciparum in vitro culture.** *P. falciparum*-infected erythrocytes were cultured in O-positive human erythrocytes in RPMI 1640 medium (Gibco, USA) containing 10% heat-inactivated pooled human sera and 5 μg/ml gentamicin (Sigma, USA). Cultures were maintained at 37°C in a gas mixture composed of 5% O₂, 5% CO₂, and 90% N₂, as described previously (41).

**Cloning of *P. falciparum* parasites by limiting dilution.** *P. falciparum*-infected erythrocytes were cultured under standard culture conditions and synchronized to ring stage using sorbitol treatment (42). Synchronous ring-stage parasites were cultured for two cycles (96 h) on a plate shaker (Gyro mini; Labnet, USA) under standard culture conditions until multiple infections were less than 1%, as determined by microscopic examination of Quickdip-stained (POCD, Australia) thin blood films. Following cell counts with a hemocytometer, cultures were diluted to 0.5 and 0.1 parasites per 200 μl (2% hematocrit), dispensed into sterile 96-well plates (Corning, USA), and incubated under standard culture conditions with medium replaced weekly. On day 16, stained thin blood smears were prepared and stained with Quickdip (POCD) and then examined by microscopy. Parasite-positive cultures were transferred into 50-mm petri dishes (Corning) and then 100-mm petri dishes (Corning) for expansion and cryopreservation. The parasite-negative wells were checked 1 week later by microscopic analysis of Quickdip-stained blood smears, and no further parasite-positive wells were identified.

**In vitro *P. falciparum* growth inhibition assays.** *In vitro* inhibition of *P. falciparum* growth was assessed using a 72-h isotopic microtest, essentially as previously described (43). Briefly, highly synchronous ring-stage *P. falciparum*-infected erythrocytes obtained by sorbitol treatment (42) were seeded at 0.5% parasitemia and 2.5% final hematocrit into 96-well tissue culture plates (3596 Costar; Corning, USA) containing serial dilutions of control or test compounds. Compound vehicle only (0.5% final DMSO) and the antimalarial drug chloroquine served as negative and positive controls, respectively, in each assay. After incubating for 48 h under standard *P. falciparum* culture conditions in RPMI 1640 medium (Gibco, USA) containing 10% heat-inactivated pooled human sera and 5 μg/ml gentamicin (Sigma, USA), 0.5 μCi [³H]-hypoxanthine (PerkinElmer, USA) was added to each well followed by culturing for a further 24 h. Cells were harvested onto 1450 MicroBeta filter mats (Wallac, USA), and [³H] incorporation was determined using a 1450 MicroBeta liquid scintillation counter (PerkinElmer). Percentage inhibition of growth for compound treated versus that for matched vehicle only (0.5% DMSO) controls was determined, and IC₅₀ values were calculated using nonlinear regression analysis in GraphPad Prism. Each compound was assayed in triplicate wells in at least three independent experiments. Statistical difference between IC₅₀ values was determined using an unpaired t test with GraphPad Prism data analysis software.

**In vitro *P. falciparum* resistance selection.** *P. falciparum* 3D7 clone C3 (3D7-C3)-infected erythrocytes were cultured with (and, in parallel, without) PS-3 at 1 × IC₅₀ (0.9 μM). Parasite growth was monitored every 1 to 3 days via microscopic examination of Quickdip-stained (POCD, Australia) thin blood films, with medium changed as needed. When PS-3-treated parasites were observed to be replicating at a similar rate to that of the untreated controls, compound pressure was gradually increased in a stepwise manner over several weeks until the parasites were surviving in 10× IC₅₀ concentrations. At this point, the selected and wild-type clones were assessed in growth inhibition assays to determine sensitivity for PS-3 and other compounds. Once a resistance phenotype was confirmed, PS-3-selected and wild-type parasites were subcloned and phenotype assessed again to confirm resistance.

**In vitro growth rate analysis of *P. falciparum*.** Highly synchronous ring-stage *P. falciparum* cultures starting at 0.25% rings and 2.5% hematocrit were cultured under standard conditions for 72 h. Quickdip-stained (POCD, Australia) thin blood films were prepared every 24 h, and ~3,000 erythrocytes...
were counted by two independent microscopists to determine the mean number of parasites infecting 100 erythrocytes at each time point. Three independent assays were assessed per clone.

**Genome sequencing.** Genomic DNA was isolated from *P. falciparum*-infected erythrocytes using a DNeasy blood and tissue kit (Qiagen, USA). The Nextera XT kit (Illumina) was used to prepare DNA libraries from samples for whole-genome sequencing using the dual index protocol. The libraries were run on the Illumina HiSeq 2500 in rapid run mode with 100-bp paired-end reads. The reads were aligned to the *P. falciparum* 3D7 reference genome (PlasmoDB v. 13.0) as described previously (44). Single nucleotide polymorphisms (SNPs) and indels were called with the Genome Analysis Toolkit’s (GATK) HaplotypeCaller (45, 46). Variants were filtered by quality scores and sequencing bias statistics based on GATK’s default filtering parameters. SNPs were filtered out if they met any of the following criteria: quality depth (QD), <2.0; mapping quality (MQ), <30.0; Phred-scaled P value using Fisher’s exact test to detect strand bias (FS), >16.0; symmetric odds ratio (SOR), >4.0; Z-score from Wilcoxon rank sum test of alternative versus reference read mapping qualities (MORankSum), less than −12.5; ReadPosRankSum (RPRS) parameter, less than −8.0. Indels were filtered out if they met any of the following criteria: QD, <10.0; RPRS, less than −20.0; FS, >200.0. Variants were annotated using snpeff (version 4.2) (47). Custom scripts were used to compare the variants between the parent sequence and the resistant clones.

**CRISPR-Cas9 genome editing.** CRISPR/Cas9 editing of mutations in *PPFK9* was performed using a pDC2-based Cas9 guide RNA (gRNA) plasmid, pDC2-cam-cocas9-U6-2-HDFHR. Two sgRNAs were designed per target site using Benchling (San Francisco, CA). For targeting of LS13, gRNA1 (CAATTATGGTTTACCATATC) and gRNA2 (TCACTATTATCATGTGTTATGA) were employed, and for targeting of RL60, gRNA3 (CATAAACATTGTAACCATGACC) and gRNA4 (GGTGCTATGAAATGTGTTATG) were used. Donor templates with 565-bp or 750-bp homology to the LS13 and RL60 target sites, respectively, were synthesized (Thermo Fisher) and cloned into the Aattl-EcoRI sites of the Cas9 vector using Gibson assembly. Plasmids were transfected by electroporation (0.31 kV, 950 μF) into Dd2 parasites and selected with 2.5 mM WR99210 for 8 days before drug pressure was removed. Editing of the recovered parasites was examined by Sanger sequencing of the bulk culture, and clonal lines were derived by limiting dilution.

**Metabolite profiling and stable isotope labeling.** Erythrocytes infected with 3D7-C3 RBS clones 1 and 3 and 3D7-3C were regularly sorbitol synchronized, and trophozoites were separated from uninfected erythrocytes using a magnet supplied by Colebrook Bioscience. The enriched infected erythrocytes (>95% parasitemia) were then allowed to recover for 0.5 to 1 h at 37°C in “complete medium” (RPMI 1640 supplemented with 0.5% AlbuMAX II, 5% human serum, 20 mM glucose [final concentration], 25 mM HEPES, 100 μM hypoxanthine, and 10 μM/μl gentamicin). Stable-isotope incorporation was performed using methods previously described with minor modifications (48). Briefly, infected erythrocytes were resuspended in fresh RPMI 1640 medium at a cellular density of 1 × 10⁸ cells/ml and allowed to recover for 10 min. Time courses were initiated by adding an equal volume of RPMI 1640 containing 11 mM 13C-U-glucose (Sigma), leading to a 1:1 mix of fully labeled/fully labeled glucose. This 1:1 mixing was performed to avoid perturbation of metabolism during label addition and allows detection of more complex labeling patterns. At predetermined time points, 1 × 10⁸ cells were aliquoted, centrifuged (15 s at 14,000 × g), washed with 1 ml ice-cold phosphate-buffered saline (PBS), and centrifuged (15 s at 14,000 × g), and metabolites were extracted with 200 μl of 80% acetonitrile (containing 1 mM 13C-U-aspartate). Samples were rapidly vortexed and centrifuged (5 min 14,000 × g), and the supernatant was collected.

The metabolites were separated on a SeQuant ZIC-pHILIC column (5 μM, 150 mm by 4.6 mm; Millipore) with a 1260 series high-pressure liquid chromatography (HPLC) system (Agilent) using a binary gradient was set up as follows: 0.5 min, 80% B; 15.5 min, 50% B; 17.5 min, 20% B; 18.5 min, 5% B; 21 min, 20% B; 23 min, 80% B; held at 80% B until 29.5 min. Detection of metabolites was performed on an Agilent Q-TOF mass spectrometer 6545 operating in negative electrospray ionization (ESI) mode. The scan range between 2 and 27 min at 0.8 spectra/second.

The drug-induced changes to the parasite metabolite profile were determined using the experimental approach described in reference 49. Drug was added at 40 μM to cell suspensions (each containing 1 × 10⁸ cells at 0.4% hematocrit), which were incubated at 37°C under controlled atmospheric conditions (5% CO₂ and 1% O₂ in N₂). After 2 h of incubation, cell suspensions were processed and metabolites were extracted for LC-MS analysis as described above.

**Isopentenyl pyrophosphate rescue.** In vitro isopentenyl pyrophosphate (IPP) pathway rescue against *P. falciparum* 3D7 parasites was carried out as previously described (39). Briefly, PS-3 was tested in *P. falciparum* in a 72-h [14C]hypoxanthine growth inhibition assay as previously described (43), with the following modifications. Two identical 72-h assays were performed simultaneously, one supplemented with 200 μM IPP and one without IPP. The antibiotic antimalarial compound clindamycin was used as a positive control. Three or more independent assays were performed, each in triplicate wells. Each compound was assayed in triplicate wells in at least three independent experiments. Statistical difference between IC₅₀'s was determined using a two-tailed t test with GraphPad Prism data analysis software.
Phosphatase activity of PHAD1 and PHAD2. Recombinant enzymes PHAD1 and PHAD2 were expressed and purified fresh as previously described in references 9 and 7, respectively. Phosphate release was quantified using the EnzChek phosphate assay kit (Invitrogen, Life Technologies) as previously described (8). In all assays, 200 ng of PHAD1 and 2,000 ng of PHAD2 were used and determined to be within the linear range for assay sensitivity (data not shown). Kinetic parameters for phosphate-containing substrate AMP (Sigma) were determined from three independent K_{cat} curves for each enzyme, with nonlinear regression analysis performed using GraphPad Prism. The K_{cat} values for AMP were determined to be 4.11 ± 0.88 mM and 4.09 ± 0.55 mM for PHAD1 and PHAD2, respectively. Inhibition of phosphatase activity for compounds PS-3, PS-3, and PS-12 was tested across a range of inhibitor concentrations (200 μM to 3 mM) at an ATP concentration of 4 mM. Nonlinear regression was attempted for inhibition curves using GraphPad Prism; unresolved “ambiguous” fitted curves indicate lack of inhibition up to 200 μM under the described assay conditions.

PFK recombinant protein expression. Recombinant proteins PfPFKα (762 to 1417 amino acids [aa]), PfPFKβ (1 to 663 aa), PfPFKα (778 to 1418 aa), and PfPFKβ (1 to 663 aa) were cloned optimised by GeneWiz and cloned between the NdeI and BamHI cloning sites of plasmid BG1861, which introduces an N-terminal 6×His tag. A catalytically dead mutant, PfPFKΔKTIDGD, was also generated utilizing Q5 site-directed mutagenesis (NEB Inc.). Constructs were transformed into the BL21(DE3) Escherichia coli expression strain (Life Technologies). Cultures were grown to an optical density at 600 nm (OD_{600}) of ~0.6 in the presence of ampicillin (100 μg/ml) at 37°C shacking at 200 rpm and induced for 2 h with isopropyl-β-D-thiogalactoside. Cells were collected by centrifugation and stored at −80°C. Pellets were resuspended in sonication lysis buffer containing 10 mM Tris-HCl (pH 7.5), 20 mM imidazole, 1 mM MgCl2, 1 mM dithiothreitol (DTT), 1 mg/ml lysozyme, 100 U Benzonase and Complete Mini EDTA-free protease inhibitor tablets (Roche Applied Science). Proteins were purified via nickel agarose beads (Gold Biotech) and eluted with 300 mM imidazole, 20 mM Tris-HCl (pH 7.5), and 150 mM NaCl. Eluted proteins were further purified via size exclusion chromatography using a HiLoad 16/60 Superdex 200 gel filtration column (GE Healthcare Life Sciences) using an AKTA Explorer 100 fast protein liquid chromatograph (FPLC) (GE Healthcare Life Sciences). Fast protein liquid chromatography buffer contained 100 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM DTT, and 10% (wt/vol) glycerol. Fractions containing purified protein were pooled, concentrated to ~2 mg/ml as determined by Pierce bicinchoninic acid (BCA) protein assay kit (Thermo Fisher), and flash frozen using liquid nitrogen (LN2) for storage at −80°C.

PFK recombinant assays. Recombinant PFK activity was measured using a linked enzyme assay as previously described (5, 7, 51). Briefly, reactions contained 100 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM DTT, 10% (wt/vol) glycerol, 0.25 mM NADH, 1 mM ATP, 3 mM fructose-6-phosphate, and excess of linking enzymes aldolase (7.5 U), triose-phosphate isomerase (3.8 U), and glyceraldehyde-3-phosphate dehydrogenase (3.8 U). Activity in the presence of inhibitors (50 μM) was tested for each recombinant protein and normalized to that for no inhibitor solvent-containing positive controls. Inhibition curves for compounds PS-3 and PS-12 were determined for PfPFKβ across the 1:2 dilution series comprising the concentration range 100 μM to 97 nM. Inhibition curves were fitted using nonlinear regression analysis using GraphPad Prism; unresolved curves indicate minimum IC_{50} values.

**PFK model construction.** PfPFK subunits were searched against the HHpred server for protein homology detection and three-dimensional (3D) structure prediction using statistics as previously described (52–55). The Borrelia burgdorferi PFK structure (PDB 1KZH [56]) returned the highest similarity for both PfPFK domains and was used to predict the 3D structure for each domain using the program MODELLER. PFK product orientation in the active site of the model was predicted via the alignment tool, using PyMOL software against the E. coli PFK crystal structure (PDB 1PFK [57]).

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**FIG S1**, PDF file, 0.3 MB.

**FIG S2**, PDF file, 0.2 MB.

**FIG S3**, PDF file, 0.2 MB.

**FIG S4**, PDF file, 0.2 MB.

**FIG S5**, PDF file, 0.2 MB.

**FIG S6**, PDF file, 0.3 MB.

**FIG S7**, PDF file, 0.2 MB.

**FIG S8**, PDF file, 0.2 MB.

**FIG S9**, PDF file, 0.4 MB.

**TABLE S1**, XLSX file, 0.1 MB.

**ACKNOWLEDGMENTS**

We thank Victoria Corey, University of California, San Diego, USA, for whole-genome sequencing analysis and the Australian Red Cross Blood Service for the provision of human blood and sera for culturing *Plasmodium* parasites.

This work was supported by an Australian National Health and Medical Research Council Post Graduate Scholarship (APP1038967), Griffith University Post Doctorate...
Fellowship, and New Researcher Grant to G.M.F., an NHMRC Primary Research Fellowship to M.J.M., NIH (R01AI103280 and R21AI123808-01 to A.O.J.), the Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital (A.O.J.), and the Burroughs Wellcome Fund (to A.O.J.).

G.M.F., S.-A.P., and K.T.A. contributed to the conception and design of the project. G.M.F., S.A.C., A.J., E.F.C., M.A., A.N.C., E.T.T., and M.C.S.L. contributed to experimental work. All authors contributed to data analysis/interpretation. G.M.F. wrote the first draft of the manuscript. All authors contributed to writing and editing sections of the manuscript.

REFERENCES


